Yep and the length of the trials does not mean a transaction(s) are not on the cards earlier. The main focus is EMD AML approval under 505(b)(2) pathway from the P2 trials. Then Zantrene may be used off-label for other indications even if trial are not completed.
This was a very interesting announcement today, lots of detail, questions and observations. Will need to let it all sink in for a couple of days - but overall positive that there is a response to Melanoma where PD-1 failed. The main question is whether this indication is commercial viable (over say ccRCC), think it may be subject to more data and input from key opinion leaders.
Ann: Zantrene Improves Immune Therapy Treatment of Melanoma, page-55
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.025(1.76%) |
Mkt cap ! $242.0M | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.45 | $1.40 | $107.5K | 75.98K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12711 | $1.41 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 1250 | 1 |
View Market Depth
| Last trade - 12.34pm 15/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |